Foresee Pharmaceuticals Announces Dosing of First Patient in Phase II/III Clinical Trial of FP-025 for Treatment of COVID-19 Associated ARDS

Foresee Pharmaceuticals Co., Ltd. announced the initiation of patient dosing in the Phase II/III clinical trial of FP-025, its highly selective oral MMP-12 inhibitor, in adult patients with severe to critical COVID-19 with associated Acute Respiratory Distress Syndrome.
[Foresee Pharmaceuticals Co., Ltd.]
Press Release
Bookmark

No account yet? Register

0
Share

Curevo Vaccine Announces the Approval to Conduct a Phase Ib Clinical Trial in South Africa to Evaluate Safety and Immunogenicity of Its Adjuvanted Subunit Investigational Vaccine, CRV-101, Against Varicella (Chickenpox) in HIV-Positive Children

Curevo Vaccine announced that approval was granted to move forward with a Phase Ib pediatric clinical trial in South Africa to evaluate the safety, efficacy, and immunogenicity of its non-live investigational vaccine, CRV-101, against varicella in immunocompromised pediatric HIV-infected populations.
[Curevo Vaccine (BusinessWire, Inc)]
Press Release
Bookmark

No account yet? Register

0
Share

Fractyl Announces First Patient Enrolled in Pivotal Study of Novel Procedural Therapy Revita® DMR for Type 2 Diabetes

Fractyl Laboratories Inc. announced the enrollment of the first patient in a pivotal clinical trial of Revita® DMR for patients with type 2 diabetes. The trial, called REVITA-T2Di, will evaluate the ability of a single Revita DMR treatment to allow patients currently on insulin therapy but with inadequate glycemic control to achieve durable insulin-free glycemic control.
[Fractyl Laboratories Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Rafael Pharmaceuticals Crosses Enrollment of 150 Patients in Pivotal Phase III Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)

Rafael Pharmaceuticals, Inc. announced that it has crossed the enrollment of 150 patients in its Phase III clinical trial for patients with relapsed or refractory AML.
[Rafael Pharmaceuticals, Inc. (GlobeNewswire, Inc.)]
Press Release
Bookmark

No account yet? Register

0
Share

Cynata Expands MEND Clinical Trial in COVID-19 and Respiratory Failure

Cynata Therapeutics Limited announced that it has received ethics committee approval to expand recruitment criteria in its active MEseNchymal coviD-19 (MEND) clinical trial.
[Cynata Therapeutics Limited (GlobeNewswire)]
Press Release
Bookmark

No account yet? Register

0
Share

Arcutis Announces First Patient Enrolled in Phase IIa Clinical Trial Evaluating ARQ-252 as a Potential Treatment for Vitiligo

Arcutis Biotherapeutics, Inc. announced enrollment of the first patient in a Phase IIa clinical trial evaluating ARQ-252 as a potential treatment for vitiligo. ARQ-252 is a potent and highly selective topical small molecule inhibitor of Janus kinase type 1.
[Arcutis Biotherapeutics, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Terns Announces Initiation of Dosing in Phase I Clinical Trial of TERN-501, its THR-Beta Agonist in Development for the Treatment of NASH

Terns Pharmaceuticals, Inc. announced the initiation of dosing in a Phase I clinical trial evaluating TERN-501, a selective thyroid hormone receptor beta (THR-β) agonist with high metabolic stability, enhanced liver distribution and greater selectivity for THR-β when compared with other THR-β agonists in development.
[Terns Pharmaceuticals, Inc. (Intrado GlobeNewswire LLC.)]
Press Release
Bookmark

No account yet? Register

0
Share

Histogen Announces Removal of Clinical Hold by FDA for HST-003 IND to Initiate a Phase I/II Trial for Knee Cartilage Regeneration

Histogen Inc. announced that the FDA has confirmed that the company satisfactorily addressed all clinical hold questions and can proceed with initiation of the planned Phase I/II clinical trial of HST-003 to evaluate the safety and efficacy of human extracellular matrix implanted within microfracture interstices and the cartilage defect in the knee to regenerate hyaline cartilage in combination with a microfracture procedure.
[Histogen Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Engineered Cells as Glioblastoma Therapeutics

Scientists focus on the use of engineered cells to treat glioblastoma, with an emphasis on data from the small number of clinical trials that have been performed to date and the lessons learned from these.
[Cancer Gene Therapy]
Ramanathan, A., & Lorimer, I. A. J. (2021). Engineered cells as glioblastoma therapeutics. Cancer Gene Therapy, 1–11. https://doi.org/10.1038/s41417-021-00320-w Cite
Full Article
Bookmark

No account yet? Register

0
Share

Chronic Myelogenous Leukemia in Childhood

Targeted therapy has markedly improved outcomes for pediatric chronic myelogenous leukemia, while raising a number of clinical questions, including the possibility of treatment-free remission and long-term health implications of prolonged tyrosine kinase inhibitors exposure at a young age.
[Current Oncology Reports]
Smith, S. M., Hijiya, N., & Sakamoto, K. M. (2021). Chronic Myelogenous Leukemia in Childhood. Current Oncology Reports, 23(4), 40. https://doi.org/10.1007/s11912-021-01025-x Cite
Abstract
Bookmark

No account yet? Register

0
Share

CARISMA Therapeutics Announces First Patient Dosed in Landmark Clinical Study Evaluating Engineered Macrophages in Humans

CARISMA Therapeutics Inc. announced that the first patient has been dosed in the Phase I multi-center clinical trial for CT-0508, a human epidermal growth factor receptor 2 targeted chimeric antigen receptor macrophage.
[CARISMA Therapeutics Inc.]
Press Release
Bookmark

No account yet? Register

0
Share
Share